Asked by: Baroness Maclean of Redditch (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government by how much demand for mental health, ADHD and autism services is increasing or decreasing in each of the past five years for people aged (1) under 16, (2) 16-24, (3) 25-34, (4) 35-49, (5) 50-64, and (6) over 65.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The following table shows the number of people in contact with National Health Service funded secondary mental health, learning disabilities and autism services, in each financial year between 2020/21 and 2024/25:
Age group | 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 |
Under 16 years old | 593,297 | 776,750 | 869,206 | 915,617 | 986,814 |
16-24 years old | 499,690 | 595,233 | 642,990 | 640,187 | 678,667 |
25-34 years old | 385,511 | 438,756 | 500,668 | 542,170 | 606,461 |
35-49 years old | 424,031 | 466,396 | 525,588 | 581,642 | 661,362 |
50-64 years old | 331,311 | 357,524 | 388,097 | 418,523 | 449,505 |
65 years old and over | 563,811 | 609,373 | 647,310 | 675,575 | 685,797 |
UNKNOWN | 5,593 | 12,663 | 9,005 | 17,112 | 60,684 |
Source: Mental Health Services Data Set (MHSDS)
Notes:
The following table shows the number of people known to be in contact with NHS Talking Therapies in each financial year between 2020/21 and 2024/25:
Age group | 2020/21 | 2021/22 | 2022/23 | 2023/24 | 2024/25 |
|
Under 16 years old | 1,222 | 1,189 | 925 | 886 | 749 |
|
16-24 years old | 360,673 | 424,826 | 398,859 | 370,377 | 350,213 |
|
25-34 years old | 487,273 | 571,094 | 563,973 | 555,142 | 543,044 |
|
35-49 years old | 437,838 | 514,275 | 537,364 | 564,755 | 583,614 |
|
50-64 years old | 265,491 | 311,633 | 332,821 | 358,120 | 366,773 |
|
65 years old and over | 89,446 | 108,885 | 123,740 | 136,297 | 140,262 |
|
Source: Improving Accessing to Psychological Therapies dataset Notes:
| ||||||
Asked by: Ben Spencer (Conservative - Runnymede and Weybridge)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions he has had with Surrey and Borders Partnership NHS Foundation Trust on meeting national targets on Autism and ADHD assessments in children.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
My Rt Hon. Friend, the Secretary of State for Health and Social Care, has regular discussions on a wide range of matters, including with trusts and integrated care boards (ICBs).
The Government has recognised that, nationally, demand for assessments for neurodevelopmental conditions such as autism and attention deficit hyperactivity disorder (ADHD) has grown significantly in recent years and that people are experiencing severe delays for accessing such assessments. The Government’s 10-Year Health Plan will make the National Health Service fit for the future and recognises the need for early intervention and support.
It is the responsibility of ICBs to make available appropriate provision to meet the health and care needs of their local population, including access to neurodevelopmental assessments.
Through the Medium-term planning framework, published 24 October, NHS England has set clear expectations for local ICBs and trusts to improve access, experience, and outcomes for autism and ADHD services over the next three years, focusing on improving quality and productivity.
Asked by: Baroness Maclean of Redditch (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what research or analysis is being carried out to understand the factors contributing to the increasing demand for mental health services, including factors other than overdiagnosis and diagnostic practices.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department funds research into mental health via the National Institute for Health and Care Research (NIHR). Through the NIHR, the Department is investigating a wide range of factors that contribute to the increase in mental health prevalence across England, including social, environmental, demographic, and biological factors. The Department also funds several population surveys that measure the national prevalence of mental health disorders.
The Department recently launched an independent review led by Professor Peter Fonagy into prevalence and support for mental health conditions, attention deficit hyperactivity disorder (ADHD), and autism. This review will examine the evidence on rising demand for mental health, autism, and ADHD services so people receive the right support at the right time and in the right place. The review will produce a short report setting out conclusions and recommendations for responding to the rising need, both within the Government and across the health system and wider public services.
Asked by: Baroness Maclean of Redditch (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what proportion of NHS funding is allocated to mental health care.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
In 2025/26, total forecast mental health spend is £15.6 billion, which works out at 8.71% of the recurrent National Health Service baseline of £179.4 billion. This was set out in a Written Ministerial Statement by my Rt Hon. Friend, the Secretary of State for Health and Social Care, on 27 March 2025.
As the Medium-Term Planning Framework makes clear, we need a new approach for mental health to drive down waits, improve the quality of care, and increase the productivity of mental health services.
Funding is a key part of this. We have set out that over the next three years, integrated care boards will be required to meet the mental health investment standard by protecting mental health spending in real terms. In other words, rising in line with inflation from 2026/27.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent assessment he has made of the use of fax machines by Shrewsbury and Telford Hospital NHS Trust.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
My Rt Hon. Friend, the Secretary of State for Health and Social Care, has instructed National Health Service trusts to stop using fax machines for anything other than business continuity. The trust has informed NHS England that they currently only use fax machines for administrative tasks.
NHS England will be meeting with the Shrewsbury and Telford Hospital NHS Trust to work with them on their decommissioning plans. As such, there is currently no date set for when fax machines will be phased out.
Asked by: Helen Morgan (Liberal Democrat - North Shropshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, when he expects fax machines to be phased out of use in Shrewsbury and Telford Hospital NHS Trust.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
My Rt Hon. Friend, the Secretary of State for Health and Social Care, has instructed National Health Service trusts to stop using fax machines for anything other than business continuity. The trust has informed NHS England that they currently only use fax machines for administrative tasks.
NHS England will be meeting with the Shrewsbury and Telford Hospital NHS Trust to work with them on their decommissioning plans. As such, there is currently no date set for when fax machines will be phased out.
Asked by: Lord Kamall (Conservative - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government, what steps they are taking to identify regulatory barriers and evaluate reimbursement policies for brain cancer therapies.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government recognises that there are currently limited treatment options available for people who have been diagnosed with cancerous brain tumours and recognises the significant impact this rare cancer can have on patients, carers, and their families. All new licensed medicines, including medicines for brain cancer, are evaluated by the National Institute for Health and Care Excellence (NICE), which makes recommendations for the National Health Service on whether they represent a clinically and cost effective use of NHS resources. NICE is actively evaluating a number of new medicines for potential use in the treatment of brain cancers.
NICE works closely with companies and the medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA), and aims to issue guidance on new medicines as close as possible to the time of licensing. The NHS in England is legally required to fund medicines recommended by NICE and funding from the Cancer Drugs Fund is available for cancer medicines from the point of a draft positive NICE recommendation, bringing forward patient access by up to five months.
The MHRA has several pathways which facilitate rapid assessment of medicines. This includes international collaborations such as Project Orbis and the Access Consortium. The MHRA has also introduced the International Recognition Pathway, which allows the MHRA to take into account the expertise and decision-making of trusted regulatory partners, and the Innovative Licensing and Access Pathway scheme, focussed on getting new and transformative medicines to patients in the UK health system more quickly. Recently, the MHRA also issued new regulations to make it faster and easier for cutting-edge cancer treatments and personalised gene therapies to be made right where patients are treated.
Asked by: Andrew Snowden (Conservative - Fylde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what discussions his Department has had with technology companies used by his Department on the automated processing of emails that contain personal health information.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department does not process personal health information. This type of information is handled by NHS England and other authorised health bodies.
We work closely with NHS England to ensure that any technology used across the health system meets the legal and ethical standards required for safeguarding personal health data. This includes data protection, information governance, and the safeguards required for handling health data. These checks ensure that any system we bring into use aligns with the rules that protect people’s privacy.
When personal data is processed as part of specific programmes, it is handled by approved delivery partners under strict governance arrangements. These partners act only on behalf of the Department and in line with data protection law and contractual controls.
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government whether they have considered changes to the use of individual funding requests for rare cancer treatments, particularly the requirement for exceptionality, for patients who have no alternative clinically appropriate treatment options.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, including metastatic ocular melanoma patients, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the National Health Service will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.
The Department remains committed to ensuring that rare cancer patients, including those with metastatic ocular melanoma, have timely access to treatment and tailored medical support.
Tebentafusp is a licensed treatment for uveal melanoma and has been recommended by the National Institute for Health and Care Excellence (NICE) and funded by NHS England since December 2024. Since funding commenced, over 100 patients have been registered to start treatment. At present, NHS England is not aware of any delays in access to Tebentafusp for eligible patients.
Alongside Tebentafusp, a policy proposition for melphalan chemosaturation was accepted onto the NHS England policy development work programme in March 2025, in line with the Methods for National Clinical Policies. Development of this policy is ongoing following receipt of the external evidence review. Progress updates are published through the NHS England Clinical Commissioning Work Programme, and NICE is concurrently updating its guidance. Until revised guidance is issued, the NHS continues to follow the recommendations in the current version.
The development of a Clinical Commissioning policy will determine both if the evidence is now sufficient to enable making the treatment routinely available and, if it is, whether to allocate service development funding to implement it across the NHS in England.
NHS England’s Individual Funding Request (IFR) Policy provides the framework through which requests outside routinely commissioned arrangements are considered. The IFR framework was last reviewed in 2022 and ensures fairness, consistency, and transparency in decision‑making across all applications relating to medicines, devices, or surgical interventions that fall within NHS England’s commissioning responsibilities.
Asked by: Baroness Finlay of Llandaff (Crossbench - Life peer)
Question to the Department of Health and Social Care:
To ask His Majesty's Government what assessment they have made of the impact of delays in commissioning decisions on (1) outcomes, and (2) quality of life, for patients with rare cancers.
Answered by Baroness Merron - Parliamentary Under-Secretary (Department of Health and Social Care)
The Government supports Scott Arthur’s Private Members Bill on rare cancers which will make it easier for clinical trials into rare cancers, including metastatic ocular melanoma patients, to take place in England by ensuring the patient population can be easily contacted by researchers. This will ensure that the National Health Service will remain at the forefront of medical innovation and is able to provide patients with the newest, most effective treatment options, and ultimately boost survival rates.
The Department remains committed to ensuring that rare cancer patients, including those with metastatic ocular melanoma, have timely access to treatment and tailored medical support.
Tebentafusp is a licensed treatment for uveal melanoma and has been recommended by the National Institute for Health and Care Excellence (NICE) and funded by NHS England since December 2024. Since funding commenced, over 100 patients have been registered to start treatment. At present, NHS England is not aware of any delays in access to Tebentafusp for eligible patients.
Alongside Tebentafusp, a policy proposition for melphalan chemosaturation was accepted onto the NHS England policy development work programme in March 2025, in line with the Methods for National Clinical Policies. Development of this policy is ongoing following receipt of the external evidence review. Progress updates are published through the NHS England Clinical Commissioning Work Programme, and NICE is concurrently updating its guidance. Until revised guidance is issued, the NHS continues to follow the recommendations in the current version.
The development of a Clinical Commissioning policy will determine both if the evidence is now sufficient to enable making the treatment routinely available and, if it is, whether to allocate service development funding to implement it across the NHS in England.
NHS England’s Individual Funding Request (IFR) Policy provides the framework through which requests outside routinely commissioned arrangements are considered. The IFR framework was last reviewed in 2022 and ensures fairness, consistency, and transparency in decision‑making across all applications relating to medicines, devices, or surgical interventions that fall within NHS England’s commissioning responsibilities.